Journal of Clinical Oncology · 2023 · 26 citations · 36 references
MedicineOncologyPediatricsChemotherapyImmunogeneticsPediatric OncologyCancer CytogeneticsPediatric Cancer BiologyPediatric Cancer GeneticsPediatric ChemotherapyPediatric LeukemiasAcute Leukemia ChemotherapyAcute Lymphoblastic Leukemia BiologyAcute Lymphoblastic Leukemia TherapyAcute Lymphoblastic Leukemia TreatmentInduction FailurePediatric Hematologic Malignancy ChemotherapyT-cell Acute Lymphoblastic Leukemia
PURPOSE Failure to respond to induction chemotherapy portends a poor outcome in childhood acute lymphoblastic leukemia (ALL) and is more frequent in T-cell ALL (T-ALL) than B-cell ALL. We aimed to address the limited understanding of clinical and genetic factors that influence outcome in a cohort of patients with T-ALL induction failure (IF). METHODS We studied all cases of T-ALL IF on two consecutive multinational randomized trials, UKALL2003 and UKALL2011, to define risk factors, treatment, and outcomes. We performed multiomic profiling to characterize the genomic landscape. RESULTS IF occurred in 10.3% of cases and was significantly associated with increasing age, occurring in 20% of patients age 16 years and older. Five-year overall survival (OS) rates were 52.1% in IF and 90.2% in responsive patients ( P < .001). Despite increased use of nelarabine-based chemotherapy consolidated by hematopoietic stem-cell transplant in UKALL2011, there was no improvement in outcome. Persistent end-of-consolidation molecular residual disease resulted in a significantly worse outcome (5-year OS, 14.3% v 68.5%; HR, 4.10; 95% CI, 1.35 to 12.45; P = .0071). Genomic profiling revealed a heterogeneous picture with 25 different initiating lesions converging on 10 subtype-defining genes. There was a remarkable abundance of TAL1 noncoding lesions, associated with a dismal outcome (5-year OS, 12.5%). Combining TAL1 lesions with mutations in the MYC and RAS pathways produces a genetic stratifier that identifies patients highly likely to fail conventional therapy (5-year OS, 23.1% v 86.4%; HR, 6.84; 95% CI, 2.78 to 16.78; P < .0001) and who should therefore be considered for experimental agents. CONCLUSION The outcome of IF in T-ALL remains poor with current therapy. The lack of a unifying genetic driver suggests alternative approaches, particularly using immunotherapy, are urgently needed.
36
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner et al. · New England Journal of Medicine · 2018 · 5.6K citations · Full text
Medicine, Hematology, Oncology +17
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger et al. · New England Journal of Medicine · 2016 · 4.4K citations · Full text
Life Sciences, Genetics, Oncology +14
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Kathryn G. Roberts, Yongjin Li, Debbie Payne-Turner et al. · New England Journal of Medicine · 2014 · 1.4K citations · Full text
Life Sciences, Genetics, Oncology +17
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia
Adolfo A. Ferrando, Donna Neuberg, Jane Staunton et al. · Cancer Cell · 2002 · 1.1K citations · Full text